Oruka Therapeutics, Inc.
ORKA
Rank in Stocks
#3308
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Share Price
$80.01
Last synced: 2026-10-21
Market Cap
$5.30B
Change (1 day)
1.16%
Change (1 year)
200.21%
Country
US
Trade Oruka Therapeutics, Inc. (ORKA)
Category
Healthcare
P/S ratio for Oruka Therapeutics, Inc. (ORKA)
P/S ratio as of 2026 TTM: 0
According to Oruka Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Oruka Therapeutics, Inc. from 2026 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
